Detalhe da pesquisa
1.
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.
PLoS Pathog
; 18(3): e1010396, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358290
2.
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.
Clin Infect Dis
; 75(7): 1232-1234, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35452519
3.
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.
J Transl Autoimmun
; 4: 100097, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33778462
4.
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
J Transl Autoimmun
; 4: 100083, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33521616
5.
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.
Front Immunol
; 12: 794638, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34868084
6.
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission.
Nat Commun
; 12(1): 3343, 2021 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099693
7.
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Int J Infect Dis
; 103: 25-32, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186704
8.
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.
HIV Clin Trials
; 19(3): 85-93, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29676212